Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
ROCKET PHARMACEUTICALS, INC. (RCKT)
Sector: Healthcare; Industry: Biotechnology

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2015-02-23 KARABELAS ARGERIS N 10%-Owner, Director Buy 603,832 $6.00 $3,622,992 Yes

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.

Insider Smart

PENN NATIONAL GAMING INC (PENN) - PENN took a deep dive from $36 to $5 due to the crash, anyone who was bold enough to pick up some shares in March or April could have made a 900% profit in 2 months. But bottom fishing is always easier said than done, if one took a safer bet and followed multiple insider buying around $18, a 100% profit is still impressive.